Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Iveric bio doses first patient in second Zimura Phase 3 clinical trial » 07:33
06/30/20
06/30
07:33
06/30/20
07:33
ISEE

Iveric bio

$5.36 /

+0.01 (+0.19%)

IVERIC bio announced the…

IVERIC bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura, a novel complement C5 inhibitor, in development for the treatment of geographic atrophy, or GA, secondary to age-related macular degeneration, or AMD. IVERIC said in a release, "The Company announced previously that Zimura met its pre-specified primary efficacy endpoint and reached statistical significance in GATHER1, also known as OPH2003, the first Phase 3 clinical trial for Zimura for the treatment of GA secondary to AMD. There are no FDA or EMA approved treatments available for patients with GA secondary to AMD."

ShowHide Related Items >><<
ISEE Iveric bio
$5.36 /

+0.01 (+0.19%)

ISEE Iveric bio
$5.36 /

+0.01 (+0.19%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
  • 18
    Jun
  • 06
    Dec
ISEE Iveric bio
$5.36 /

+0.01 (+0.19%)

On The Fly
Fly Intel: Pre-market Movers » 09:08
06/18/20
06/18
09:08
06/18/20
09:08
ORN

Orion Group

$3.31 /

+0.305 (+10.15%)

, ENPH

Enphase Energy

$39.01 /

-13.56 (-25.79%)

, CMC

Commercial Metals

$19.42 /

-0.215 (-1.09%)

, FRAN

Francesca's

$3.68 /

-0.63 (-14.62%)

, FLWS

1-800-Flowers.com

$22.93 /

+0.32 (+1.42%)

, KR

Kroger

$32.82 /

+0.275 (+0.85%)

, CCL

Carnival

$19.09 /

-1.34 (-6.56%)

, DBI

Designer Brands

$7.34 /

-0.65 (-8.14%)

, CBIO

Catalyst Biosciences

$7.26 /

-0.58 (-7.40%)

, ISEE

Iveric bio

$4.47 /

+0.005 (+0.11%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ORN Orion Group
$3.31 /

+0.305 (+10.15%)

KR Kroger
$32.82 /

+0.275 (+0.85%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

FRAN Francesca's
$3.68 /

-0.63 (-14.62%)

FLWS 1-800-Flowers.com
$22.93 /

+0.32 (+1.42%)

ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

DBI Designer Brands
$7.34 /

-0.65 (-8.14%)

CMC Commercial Metals
$19.42 /

-0.215 (-1.09%)

CCL Carnival
$19.09 /

-1.34 (-6.56%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

ORN Orion Group
$3.31 /

+0.305 (+10.15%)

07/08/19
Fly Intel: Top five analyst upgrades
07/08/19 B. Riley FBR
B. Riley FBR upgrades Orion Group to Buy, says pullback overdone
07/08/19 B. Riley FBR
Orion Group upgraded to Buy from Neutral at B. Riley FBR
ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

06/18/20 Johnson Rice
Enphase Energy upgraded to Buy from Accumulate at Johnson Rice
06/18/20 Cowen
Cowen sees 'compelling' buying opportunity after Enphase short report
06/18/20 Roth Capital
Enphase Energy short report brings buying opportunity, says Roth Capital
05/28/20 JPMorgan
Enphase Energy price target raised to $67 from $54 at JPMorgan
CMC Commercial Metals
$19.42 /

-0.215 (-1.09%)

06/08/20 Citi
Commercial Metals downgraded at Citi on valuation, scrap costs
06/08/20 Citi
Commercial Metals downgraded to Neutral from Buy at Citi
05/06/20 BofA
Steel Dynamics downgraded to Underperform from Neutral at BofA
03/17/20 BofA
Commercial Metals upgraded to Buy from Underperform at BofA
FRAN Francesca's
$3.68 /

-0.63 (-14.62%)

FLWS 1-800-Flowers.com
$22.93 /

+0.32 (+1.42%)

06/02/20
1-800-Flowers.com cut to Underperform at DA Davidson on impending recession
06/02/20 DA Davidson
1-800-Flowers.com downgraded to Underperform from Neutral at DA Davidson
04/13/20 DA Davidson
1-800-Flowers.com downgraded to Neutral from Buy at DA Davidson
04/13/20 DA Davidson
1-800-Flowers.com downgraded to Neutral from Buy at DA Davidson
KR Kroger
$32.82 /

+0.275 (+0.85%)

06/15/20 UBS
Kroger price target raised to $35 from $33 at UBS
06/11/20 Oppenheimer
Roku price target raised to $140 from $135 at Oppenheimer
06/11/20 BMO Capital
Kroger price target raised to $34 from $31 at BMO Capital
04/15/20 Citi
Kroger assumed with a Neutral from Buy at Citi
CCL Carnival
$19.09 /

-1.34 (-6.56%)

06/18/20 Berenberg
Carnival downgraded to Sell from Hold at Berenberg
06/11/20 JPMorgan
Carnival price target raised to $20 from $16 at JPMorgan
06/09/20 Stifel
Carnival price target raised to $30 from $17 at Stifel
06/03/20
Fly Intel: Top five analyst downgrades
DBI Designer Brands
$7.34 /

-0.65 (-8.14%)

05/18/20 Standpoint Research
Designer Brands upgraded to Buy from Hold at Standpoint Research
04/06/20
Fly Intel: Top five analyst downgrades
04/06/20 Susquehanna
Designer Brands downgraded to Neutral at Susquehanna
04/05/20 Susquehanna
Designer Brands downgraded to Neutral from Positive at Susquehanna
CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
ORN Orion Group
$3.31 /

+0.305 (+10.15%)

KR Kroger
$32.82 /

+0.275 (+0.85%)

FRAN Francesca's
$3.68 /

-0.63 (-14.62%)

FLWS 1-800-Flowers.com
$22.93 /

+0.32 (+1.42%)

ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

DBI Designer Brands
$7.34 /

-0.65 (-8.14%)

CMC Commercial Metals
$19.42 /

-0.215 (-1.09%)

CCL Carnival
$19.09 /

-1.34 (-6.56%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

  • 18
    Jun
  • 18
    Jun
KR Kroger
$32.82 /

+0.275 (+0.85%)

FLWS 1-800-Flowers.com
$22.93 /

+0.32 (+1.42%)

ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

CCL Carnival
$19.09 /

-1.34 (-6.56%)

KR Kroger
$32.82 /

+0.275 (+0.85%)

ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

DBI Designer Brands
$7.34 /

-0.65 (-8.14%)

CCL Carnival
$19.09 /

-1.34 (-6.56%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

KR Kroger
$32.82 /

+0.275 (+0.85%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

FRAN Francesca's
$3.68 /

-0.63 (-14.62%)

ENPH Enphase Energy
$39.01 /

-13.56 (-25.79%)

CMC Commercial Metals
$19.42 /

-0.215 (-1.09%)

CCL Carnival
$19.09 /

-1.34 (-6.56%)

Syndicate
Iveric bio 24.536M share Spot Secondary priced at $4.099 » 06:15
06/18/20
06/18
06:15
06/18/20
06:15
ISEE

Iveric bio

$4.47 /

+0.005 (+0.11%)

Cowen and Credit Suisse…

Cowen and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
  • 18
    Jun
ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

On The Fly
Fly Intel: After-Hours Movers » 19:02
06/17/20
06/17
19:02
06/17/20
19:02
ABM

ABM

$32.68 /

-1.43 (-4.19%)

, ELOX

Eloxx Pharmaceuticals

$3.06 /

-0.05 (-1.61%)

, IBTX

Independent Bank

$39.41 /

-1.99 (-4.81%)

, NDLS

Noodles & Company

$5.19 /

-0.135 (-2.54%)

, NLTX

Neoleukin Therapeutics

$13.52 /

+0.19 (+1.43%)

, TMUS

T-Mobile

$102.73 /

-0.23 (-0.22%)

, HUD

Hudson

$6.22 /

-0.37 (-5.61%)

, TISI

Team

$6.57 /

+0.355 (+5.71%)

, QUIK

QuickLogic

$4.33 /

-0.38 (-8.07%)

, LPTX

Leap Therapeutics

$2.57 /

-0.02 (-0.77%)

, ADMS

Adamas Pharmaceuticals

$2.86 /

-0.07 (-2.39%)

, CBIO

Catalyst Biosciences

$7.26 /

-0.58 (-7.40%)

, ISEE

Iveric bio

$4.47 /

+0.005 (+0.11%)

, KTOS

Kratos Defense

$17.45 /

-0.11 (-0.63%)

, X

U.S. Steel

$9.37 /

-1.1 (-10.51%)

, KIDS

OrthoPediatrics

$49.51 /

-0.78 (-1.55%)

, FOXF

Fox Factory

$82.63 /

-1.28 (-1.53%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
X U.S. Steel
$9.37 /

-1.1 (-10.51%)

TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

TISI Team
$6.57 /

+0.355 (+5.71%)

QUIK QuickLogic
$4.33 /

-0.38 (-8.07%)

NLTX Neoleukin Therapeutics
$13.52 /

+0.19 (+1.43%)

NDLS Noodles & Company
$5.19 /

-0.135 (-2.54%)

LPTX Leap Therapeutics
$2.57 /

-0.02 (-0.77%)

KTOS Kratos Defense
$17.45 /

-0.11 (-0.63%)

KIDS OrthoPediatrics
$49.51 /

-0.78 (-1.55%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

IBTX Independent Bank
$39.41 /

-1.99 (-4.81%)

HUD Hudson
$6.22 /

-0.37 (-5.61%)

FOXF Fox Factory
$82.63 /

-1.28 (-1.53%)

ELOX Eloxx Pharmaceuticals
$3.06 /

-0.05 (-1.61%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

ADMS Adamas Pharmaceuticals
$2.86 /

-0.07 (-2.39%)

ABM ABM
$32.68 /

-1.43 (-4.19%)

ABM ABM
$32.68 /

-1.43 (-4.19%)

05/27/20 Sidoti
ABM downgraded to Neutral at Sidoti following bounce back from lows
05/27/20 Sidoti
ABM downgraded to Neutral from Buy at Sidoti
04/08/20 Maxim
NV5 Global, ABM Industries, Badger Meter cut to Hold at Maxim
04/08/20 Maxim
ABM downgraded to Hold from Buy at Maxim
ELOX Eloxx Pharmaceuticals
$3.06 /

-0.05 (-1.61%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
IBTX Independent Bank
$39.41 /

-1.99 (-4.81%)

06/02/20 Jefferies
Texas Capital resumed with a Hold at Jefferies
05/26/20 Raymond James
Independent Bank upgraded to Outperform from Market Perform at Raymond James
05/26/20 Raymond James
Independent Bank upgraded to Outperform from Market Perform at Raymond James
05/26/20 Keefe Bruyette
Texas Capital downgraded to Market Perform from Outperform at Keefe Bruyette
NDLS Noodles & Company
$5.19 /

-0.135 (-2.54%)

02/14/20 Maxim
Noodles & Company initiated with a Buy at Maxim
02/14/20 Maxim
Noodles & Company initiated with a Buy at Maxim
12/10/19 Jefferies
Burger King, Dunkin, Del Taco best positioned QSRs for alt meats, says Jefferies
10/17/19 Jefferies
Noodles & Company same-sale-sales momentum continued in Q3, says Jefferies
NLTX Neoleukin Therapeutics
$13.52 /

+0.19 (+1.43%)

06/17/20 Mizuho
Neoleukin Therapeutics initiated with a Buy at Mizuho
04/13/20 H.C. Wainwright
Neoleukin Therapeutics initiated with a Buy at H.C. Wainwright
03/16/20
Fly Intel: Top five analyst initiations
03/16/20 BofA
Neoleukin Therapeutics initiated with a Buy at BofA
TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

06/12/20 Deutsche Bank
Deutsche Bank still believes Dish acquisition of Boost will close
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
06/09/20
Fly Intel: Top five analyst downgrades
06/09/20 Guggenheim
T-Mobile downgraded to Neutral on valuation at Guggenheim
HUD Hudson
$6.22 /

-0.37 (-5.61%)

03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
02/04/20 UBS
Hudson downgraded to Neutral from Buy at UBS
11/05/19
Fly Intel: Top five analyst downgrades
11/05/19 BofA
Hudson downgraded to Underperform from Neutral at BofA/Merrill
TISI Team
$6.57 /

+0.355 (+5.71%)

12/12/19 Sidoti
Team initiated with a Buy at Sidoti
QUIK QuickLogic
$4.33 /

-0.38 (-8.07%)

02/13/20 Craig-Hallum
QuickLogic price target lowered to $8.50 from $14 at Craig-Hallum
01/13/20 Roth Capital
QuickLogic price target raised to $8.50 from 35c at Roth Capital
01/13/20 Oppenheimer
QuickLogic price target raised to $14 from $1 at Oppenheimer
08/15/19
Fly Intel: Top five analyst initiations
LPTX Leap Therapeutics
$2.57 /

-0.02 (-0.77%)

02/10/20 Baird
Leap Therapeutics initiated with an Outperform at Baird
01/08/20 Raymond James
Raymond James upgrades Leap Therapeutics to Outperform on BeiGene deal
01/08/20 Raymond James
Leap Therapeutics upgraded to Outperform from Market Perform at Raymond James
11/15/19 Raymond James
Raymond James cuts Leap Therapeutics to Market Perform after TRX518 shelved
ADMS Adamas Pharmaceuticals
$2.86 /

-0.07 (-2.39%)

12/18/19 H.C. Wainwright
Adamas Pharmaceuticals price target lowered to $10 from $30 at H.C. Wainwright
12/17/19 JMP Securities
JMP keeps Outperform rating, $16 target on Adamas based on Gocovri potential
12/17/19 William Blair
Adamas shares undervalued despite ADS-5102 disappointment, says William Blair
12/17/19 Evercore ISI
Adamas' new team can now execute with 'clean slate,' says Evercore ISI
CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
KTOS Kratos Defense
$17.45 /

-0.11 (-0.63%)

04/06/20 Canaccord
Kratos Defense acquisition provides long-term opportunity, says Canaccord
03/18/20 Benchmark
Benchmark starts Kratos Defense at Buy, sees 'commanding' lead in drones
03/18/20 Benchmark
Kratos Defense initiated with a Buy at Benchmark
03/11/20 SunTrust
Kratos Defense upgraded to Buy from Hold at SunTrust
X U.S. Steel
$9.37 /

-1.1 (-10.51%)

06/09/20 GLJ Research
U.S. Steel upgraded to Hold from Sell at GLJ Research
03/23/20 BMO Capital
U.S. Steel price target lowered to $6 from $9 at BMO Capital
01/31/20 BMO Capital
U.S. Steel price target lowered to $10 from $14 at BMO Capital
01/14/20 Goldman Sachs
U.S. Steel reinstated with a Sell at Goldman Sachs
KIDS OrthoPediatrics
$49.51 /

-0.78 (-1.55%)

06/16/20 Stifel
OrthoPediatrics price target raised to $55 from $48 at Stifel
06/08/20 BTIG
OrthoPediatrics price target raised to $54 from $48 at BTIG
05/06/20 Piper Sandler
OrthoPediatrics trends in April not as bad as feared, says Piper Sandler
03/30/20 Piper Sandler
OrthoPediatrics will bounce back well post COVID-19, says Piper Sandler
FOXF Fox Factory
$82.63 /

-1.28 (-1.53%)

06/16/20 CJS Securities
Fox Factory downgraded to Market Perform from Outperform at CJS Securities
05/29/20
Fly Intel: Top five analyst upgrades
05/29/20 BofA
Fox Factory upgraded to Buy from Neutral at BofA
05/29/20 BofA
Fox Factory upgraded to Buy from Neutral at BofA
X U.S. Steel
$9.37 /

-1.1 (-10.51%)

TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

TISI Team
$6.57 /

+0.355 (+5.71%)

QUIK QuickLogic
$4.33 /

-0.38 (-8.07%)

NLTX Neoleukin Therapeutics
$13.52 /

+0.19 (+1.43%)

NDLS Noodles & Company
$5.19 /

-0.135 (-2.54%)

LPTX Leap Therapeutics
$2.57 /

-0.02 (-0.77%)

KTOS Kratos Defense
$17.45 /

-0.11 (-0.63%)

KIDS OrthoPediatrics
$49.51 /

-0.78 (-1.55%)

IBTX Independent Bank
$39.41 /

-1.99 (-4.81%)

HUD Hudson
$6.22 /

-0.37 (-5.61%)

FOXF Fox Factory
$82.63 /

-1.28 (-1.53%)

ELOX Eloxx Pharmaceuticals
$3.06 /

-0.05 (-1.61%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

ADMS Adamas Pharmaceuticals
$2.86 /

-0.07 (-2.39%)

ABM ABM
$32.68 /

-1.43 (-4.19%)

  • 18
    Jun
  • 19
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
X U.S. Steel
$9.37 /

-1.1 (-10.51%)

TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

IBTX Independent Bank
$39.41 /

-1.99 (-4.81%)

X U.S. Steel
$9.37 /

-1.1 (-10.51%)

TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

NLTX Neoleukin Therapeutics
$13.52 /

+0.19 (+1.43%)

NDLS Noodles & Company
$5.19 /

-0.135 (-2.54%)

LPTX Leap Therapeutics
$2.57 /

-0.02 (-0.77%)

KTOS Kratos Defense
$17.45 /

-0.11 (-0.63%)

HUD Hudson
$6.22 /

-0.37 (-5.61%)

CBIO Catalyst Biosciences
$7.26 /

-0.58 (-7.40%)

ADMS Adamas Pharmaceuticals
$2.86 /

-0.07 (-2.39%)

X U.S. Steel
$9.37 /

-1.1 (-10.51%)

TMUS T-Mobile
$102.73 /

-0.23 (-0.22%)

TISI Team
$6.57 /

+0.355 (+5.71%)

ISEE Iveric bio
$4.47 /

+0.005 (+0.11%)

ABM ABM
$32.68 /

-1.43 (-4.19%)

Syndicate
Iveric bio announces $50M common stock offering, concurrent private placement » 16:04
06/17/20
06/17
16:04
06/17/20
16:04
ISEE

Iveric bio

$4.48 /

+0.02 (+0.45%)

Iveric bio announced that…

Iveric bio announced that it is commencing an underwritten public offering of $50M of shares of its common stock Concurrent with the public offering, the company has agreed to sell, subject to the consummation of the public offering and other customary conditions, in a private placement, $35Mof its common stock to affiliates of Vivo Capital and Samsara BioCapital, at a sale price equal to the price of the common stock sold to the public in the public offering. The consummation of the public offering is not contingent on the consummation of the concurrent private placement. Cowen and Credit Suisse are acting as the book-running managers for the public offering and as placement agents for the concurrent private placement. Wedbush PacGrow is acting as lead manager for the public offering.

ShowHide Related Items >><<
ISEE Iveric bio
$4.48 /

+0.02 (+0.45%)

ISEE Iveric bio
$4.48 /

+0.02 (+0.45%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
ISEE Iveric bio
$4.48 /

+0.02 (+0.45%)

ISEE Iveric bio
$4.48 /

+0.02 (+0.45%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
06/15/20
06/15
08:58
06/15/20
08:58
CTLT

Catalent

$69.58 /

+0.87 (+1.27%)

, MRNA

Moderna

$62.00 /

+1.84 (+3.06%)

, SHOP

Shopify

$744.50 /

+19.615 (+2.71%)

, BYSI

BeyondSpring

$16.67 /

+0.11 (+0.66%)

, ISEE

Iveric bio

$3.83 /

+0.08 (+2.13%)

, AZN

AstraZeneca

$51.46 /

-0.11 (-0.21%)

, IRBT

iRobot

$75.33 /

+0.765 (+1.03%)

, JKS

JinkoSolar

$17.84 /

+0.9 (+5.31%)

, BP

BP

$24.74 /

+0.67 (+2.78%)

, HTZ

Hertz

$2.86 /

+0.84 (+41.58%)

, CBIO

Catalyst Biosciences

$7.44 /

+0.31 (+4.35%)

, XOG

Extraction Oil & Gas

$0.64 /

+0.0601 (+10.36%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MRNA Moderna
$62.00 /

+1.84 (+3.06%)

06/12/20 Piper Sandler
Moderna preclinical data supports activity of COVID vaccine, says Piper Sandler
06/11/20 Piper Sandler
Moderna, FDA finalize Phase III trial protocol for mRNA-1273, says Piper Sandler
06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
SHOP Shopify
$744.50 /

+19.615 (+2.71%)

06/15/20 Piper Sandler
Shopify upgraded to Overweight from Neutral at Piper Sandler
06/03/20
Zoom Video upgraded to Buy at DA Davidson on 'huge acceleration in growth'
05/21/20 Roth Capital
Roth boosts Shopify target to $750, says valuation remains 'stretched'
05/21/20 Canaccord
Shopify price target raised to $700 from $650 at Canaccord
BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
02/07/20 Jefferies
BeyondSpring initiated with a Buy at Jefferies
ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
IRBT iRobot
$75.33 /

+0.765 (+1.03%)

05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 JPMorgan
iRobot upgraded to Neutral on encouraging trends at JPMorgan
05/26/20 JPMorgan
iRobot upgraded to Neutral from Underweight at JPMorgan
05/18/20
Dougherty upgrades iRobot to Buy amid fall in house cleaning services
JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

04/08/20 GLJ Research
JinkoSolar price target lowered to $6.88 from $7.97 at GLJ Research
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
02/11/20 CICC
JinkoSolar upgraded to Outperform from Neutral at CICC
10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
BP BP
$24.74 /

+0.67 (+2.78%)

06/05/20 UBS
UBS reiterates Buy on BP
06/05/20 UBS
UBS backs Buy on Premier Oil after revised terms for BP assets
06/02/20 Wolfe Research
BP upgraded to Outperform from Peer Perform at Wolfe Research
05/28/20 Societe Generale
BP downgraded to Hold from Buy at Societe Generale
HTZ Hertz
$2.86 /

+0.84 (+41.58%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

04/23/20 Imperial Capital
Extraction Oil & Gas rating withdrawn at Imperial Capital
04/03/20 Wells Fargo
Wells Fargo says oil markets heading into eye of 'perfect storm' in Q2
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Extraction Oil & Gas downgraded to Underweight from Equal Weight at Stephens
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

Hot Stocks
Iveric bio announces 18-month Zimura trial data » 06:22
06/15/20
06/15
06:22
06/15/20
06:22
ISEE

Iveric bio

$3.83 /

+0.08 (+2.13%)

Iveric bio announced…

Iveric bio announced 18-month results from the company's first Phase 3 clinical trial for Zimura, a novel complement C5 inhibitor, for the treatment of geographic atrophy, or GA, secondary to age-related macular degeneration, or AMD. The 18-month data supports the previously announced 12-month data from this trial, at which time point Zimura met the pre-specified primary efficacy endpoint with statistical significance. The reduction in the mean rate of GA growth over 18 months was 28.11% for the Zimura 2 mg group as compared to the corresponding sham control group and 29.97% for the Zimura 4 mg group as compared to the corresponding sham control group. The pre-specified efficacy analysis for the primary endpoint was performed at month 12 using all of the power in the trial to detect a statistically significant difference. Therefore, the p-values for the 18 month statistical analyses are descriptive in nature. The descriptive p-values for the treatment effects at month 18 were 0.0014 for the Zimura 2 mg group and 0.0021 for the Zimura 4 mg group. In this trial, the treatment effect was observed as early as six months, with an increase in the absolute difference of the mean change in GA growth for treatment with either Zimura 2 mg or Zimura 4 mg, as compared to sham, at each subsequent time point, suggesting the progressive benefit of continuous treatment with Zimura. Zimura maintained its favorable safety profile at 18 months with no reported Zimura related adverse events, no cases of endophthalmitis and a lower rate of choroidal neovascularization, or CNV, than reported for C3 inhibition. The overall 18 month data may suggest a dose response relationship. Mean rate of change in GA growth over 18 months, was measured by fundus autofluorescence, or FAF, based on readings at four time points (baseline, month 6, month 12 and month 18) and was calculated using the square root transformation of the GA area. The FAF images were assessed by an independent masked reading center. The prespecified statistical analysis plan used a model of repeated measures, or MRM, to compare data for the Zimura 2 mg and Zimura 4 mg groups to the corresponding sham groups. Zimura was generally well tolerated after 18 months of administration. There was no Zimura-related inflammation, no Zimura-related discontinuations from the trial, no cases of endophthalmitis and no Zimura-related adverse events. Through month 18, the reported incidence of CNV in the untreated fellow eye was 11 patients and in the study eye was 3 patients in the sham control group, 8 patients in the Zimura 2 mg group and 13 patients in the Zimura 4 mg group. The most frequently reported ocular adverse events were related to the injection procedure.

ShowHide Related Items >><<
ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

Over a quarter ago
Hot Stocks
Iveric bio announces fast track designation for Zimura from FDA » 08:03
04/03/20
04/03
08:03
04/03/20
08:03
ISEE

Iveric bio

$3.17 /

+0.02 (+0.63%)

Iveric bio announced that…

Iveric bio announced that the FDA has granted fast track designation to Zimura, a novel complement C5 inhibitor, in development for the treatment of geographic atrophy, or GA, secondary to dry age-related macular degeneration, or AMD.

ShowHide Related Items >><<
ISEE Iveric bio
$3.17 /

+0.02 (+0.63%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
Hot Stocks
Iveric bio names Pravin U. Dugel chief strategy and business officer » 16:03
03/23/20
03/23
16:03
03/23/20
16:03
ISEE

Iveric bio

$2.92 /

-0.08 (-2.67%)

Iveric bio announced the…

Iveric bio announced the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer, effective April 1, 2020. In this role, Dr. Dugel will help shape IVERIC bio's business development strategy going forward. "We are excited to add Pravin to our management team," stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio. "In addition to being a globally recognized retinal specialist, Pravin brings an extensive network and long-standing relationships with the biotech/pharma ophthalmic industry. With IVERIC bio's portfolio of multiple ongoing retinal disease therapeutic and gene therapy R&D programs, Pravin's experience will be instrumental in helping us build alliances with potential future collaborators and other stakeholders. We look forward to Pravin's input and perspective as we move the Company forward." Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona.

ShowHide Related Items >><<
ISEE Iveric bio
$2.92 /

-0.08 (-2.67%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
Hot Stocks
Iveric bio delays initiation of enrollment for Zimura pivotal clinical trial » 08:14
03/18/20
03/18
08:14
03/18/20
08:14
ISEE

Iveric bio

$3.74 /

+0.015 (+0.40%)

Iveric bio announced that…

Iveric bio announced that due to the threat of the coronavirus (COVID-19) global pandemic, the company has decided to delay the initiation of enrollment of patients in the second pivotal clinical trial for Zimura, a novel complement C5 inhibitor, in development for the treatment of geographic atrophy, or GA, secondary to dry age-related macular degeneration, or AMD. "In light of the COVID-19 pandemic and out of an abundance of caution for the safety and well-being of our elderly patients and participating physicians and their staffs, we have decided to delay the initiation of enrollment in our second pivotal trial of Zimura in geographic atrophy secondary to dry AMD, the ISEE2008 trial, which was on track to begin this month," stated Glenn Sblendorio, CEO and President of IVERIC bio. "It is critically important that we heed the warnings from the U.S. Centers for Disease Control, World Health Organization and national, state and local governments during this time of uncertainty. We will continue to closely monitor the situation in the United States and abroad to determine when enrollment should begin." Kourous Rezaei, M.D., Chief Medical Officer of IVERIC bio said, "Our first priority is to ensure the best interest of our patients, caregivers, and physicians. We want to thank clinical investigators and their teams for their enthusiasm and support in completing the activities necessary to begin enrolling patients at a number of clinical sites, including identification of potential patients for this trial. We will continue our efforts to prepare additional clinical sites, so that we can begin enrolling patients expeditiously, once the COVID-19 threat dissipates."

ShowHide Related Items >><<
ISEE Iveric bio
$3.74 /

+0.015 (+0.40%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.